Brightsurf Science News & Current Events

October 25, 2020
The effects of social determinants of health on kidney transplant candidates
Social determinants of health are associated with patient-reported outcomes in adults who are eligible to undergo kidney transplantation evaluations.

Gender, age divide in new bullying study
Students' emotional resilience is linked to their chances of being victimised, with less resilient students more likely to suffer from harassment, new research shows.

Globalized economy making water, energy and land insecurity worse: Study
The first large-scale study of the risks that countries face from dependence on water, energy and land resources has found that globalisation may be decreasing, rather than increasing, the security of global supply chains.

Study reveals details behind transplant disparities experienced by black patients
In an analysis of information on patients with kidney failure, Black patients are less likely than white patients to be placed on transplant waiting lists.

Oncotarget: Survival after resection of brain metastases: A matched cohort analysis
The cover for issue 32 of Oncotarget features Figure 2, ''This figure depicts overall survival and local in-brain recurrence-free survival in the study's subgroups,'' by Hussein, et al. which reported that the aim of the present study is to assess whether the use of 5-ALA has an impact on local recurrence or survival compared to conventional white light microscopic tumor resection.

Inhibitor of KRAS gene mutation shows promise in lung, bowel and other solid tumors
New results from a clinical trial of a drug that targets a cancer-causing mutation in the KRAS gene have shown that it can shrink tumours and is well-tolerated by patients.

Indian and Pakistani women diagnosed with more aggressive breast cancer at younger age
Indian and Pakistani women are diagnosed with breast cancer, including more aggressive forms of the disease, at a younger age, according to Rutgers researchers.

Targeted inhibitor of mutated KRAS gene shows promise in lung, bowel, & other solid tumors
A novel agent that targets a mutated form of the KRAS gene - the most commonly altered oncogene in human cancers and one long considered ''undruggable'' - shrank tumors in most patients in a clinical trial with manageable side effects, researchers reported today at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Therapeutic, which is taking place online.

Next generation BRAF inhibitor cancer drug shows promise in early patient trial
A new drug designed to work on cancers with an altered BRAF gene has shown promise in an early patient trial presented at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.